CD274 and neoplasm: In patients with non-small cell lung cancer (NSCLC), the expression of programmed death-ligand-1 (PD-L1) on tumor cell surfaces has become a pivotal predictive biomarker guiding treatment decisions with immune checkpoint inhibitors (ICIs) directed against programmed death-1 (PD-1) and PD-L1 [1].